Form fit function.png
Conformis Announces Achievement of Third Milestone Under Development and License Agreements
22 avr. 2021 16h30 HE | Conformis, Inc.
BILLERICA, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific...
Form fit function.png
Conformis Announces Achievement of Second Milestone Under Development and License Agreements
20 août 2020 07h30 HE | Conformis, Inc.
BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17 déc. 2018 07h50 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06 déc. 2018 07h50 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04 déc. 2018 07h50 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Ascom_rot.png
Ascom announces partnership with Stryker to deliver Stryker iBed wireless notifications to clinicians to target fall prevention
28 août 2018 08h00 HE | Ascom Holding AG
BAAR, Switzerland, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, announced a new North American...
Stryker R&D Executive to Speak at Clinical Research Conference on December 4, 2013
26 nov. 2013 09h01 HE | Clinical Research in Georgia
ATLANTA, GA--(Marketwired - Nov 26, 2013) - Marc Long, PhD, Senior Director, Technology and Innovation, Stryker Orthobiologics, will provide a keynote address at the second annual Clinical Research...
Dean Goetz Lawyer and John Gomez Secure $8.34 Million for Plaintiff Loren Kransky in DePuy ASP Hip Lawsuit
02 août 2013 16h26 HE | Dean Goetz Law Firm
SAN DIEGO, CA--(Marketwired - Aug 2, 2013) - Due to a defective DePuy ASR XL hip implant, Loren Kransky was given less than six months to live. The amounts of cobalt and chromium metal levels in...